EnteroMedics Inc. (ETRM) was a big mover last session, as the company saw its shares rise by nearly 64% on the day on the back of positive study data for its obesity treatment Maestro system. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend of the company, as the stock is now trading above the near-flat price range of $1.27 to $1.40 in the past one-month time frame.
The company has seen one negative estimate revision in the past 30 days and its Zacks Consensus Estimate moved a notch lower, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
EnteroMedics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.
Some better-ranked stocks in the medical products sector include NuVasive, Inc. (NUVA), Hill-Rom Holdings, Inc. (HRC) and Exactech Inc. (EXAC). While NuVasive and Hill-Rom Holdings hold a Zacks Rank #1 (Strong Buy), Exactech carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment